| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. | N Engl J Med | 2009 | 14.31 |
| 2 | Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. | Gastroenterology | 2010 | 6.14 |
| 3 | Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. | Lancet Infect Dis | 2012 | 2.41 |
| 4 | Racial differences in hepatitis C treatment eligibility. | Hepatology | 2011 | 1.28 |
| 5 | Assessment of the patient who failed treatment for chronic hepatitis C. | Gastroenterol Nurs | 2005 | 0.75 |